Information, not a decision

Diffuse large B-cell lymphoma: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 11 Nov 2026

Open trials (378)

NCT06002659	Phase 1/2	CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)	Recruiting
NCT07735533	Phase 1/2	A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies	Recruiting
NCT07409428	Phase 3	A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL	Recruiting
NCT06806033	Phase 2	Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL	Recruiting
NCT06717347	Phase 3	A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)	Recruiting
NCT03223610	Phase 1/2	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	Recruiting
NCT04002947	Phase 2	Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma	Recruiting
NCT06649812	Phase 2	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma	Recruiting
NCT07654426	Phase 2	The CARDIOPROTECT Trial	Not yet recruiting
NCT07249905	Phase 1/2	Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma	Recruiting
NCT07517705	Phase 2	MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma	Not yet recruiting
NCT07917754	Phase 2/3	A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)	Not yet recruiting

366 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

No phase 3 trial in this list ended in the last 90 days.

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 11 Nov 2026

https://frontlightresearch.com/en/doctor/diffuse-large-b-cell-lymphoma/tumor-board